Conditions: Chronic Hepatitis C Hepatitis C Virus HCV
Keywords: HCV GT1 Non-cirrhotic RBV Free Without cirrhosis Chronic Hepatitis C Hepatitis C Genotype 1 (GT1) IFN free Hepatitis C Ribavirin Free Interferon (IFN) Free HCV Hepatitis C virus DAA
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 703
Healthy volunteers: no

Brief summary:
This study seeks to evaluate the efficacy and safety of ABT-493/ABT-530 in participants with Genotype 1 hepatitis C virus infection without cirrhosis

Detailed description:

Arms:
arm 1: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 12 weeks. arm 2: ABT-493/ABT-530 (300 mg/120 mg) coformulated once daily (QD) for 8 weeks.

Interventions: intervention 1: ABT-493/ABT-530
Intervention descriptions: intervention 1: Tablet; ABT-493 coformulated with ABT-530

Protocol document: